Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Low-density lipoprotein-lowering strategies: target versus maximalist versus population percentile.

Sniderman AD, De Graaf J, Couture P.

Curr Opin Cardiol. 2012 Jul;27(4):405-11. doi: 10.1097/HCO.0b013e328353fed5. Review.

PMID:
22573170
2.
3.

Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: Post-hoc analyses from the U.K. InPractice study.

Idris I, Tate H, Ahmad A, McCormack T.

J Clin Lipidol. 2011 Jul-Aug;5(4):316-23. doi: 10.1016/j.jacl.2011.06.001. Epub 2011 Jun 12.

PMID:
21784378
5.

Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.

Soran H, France MW, Kwok S, Dissanayake S, Charlton-Menys V, Younis NN, Durrington PN.

Ann Clin Biochem. 2011 Nov;48(Pt 6):566-71. doi: 10.1258/acb.2011.010277. Epub 2011 Oct 17.

PMID:
22006975
6.

Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice.

Sniderman AD.

J Clin Lipidol. 2008 Feb;2(1):36-42. doi: 10.1016/j.jacl.2007.12.006. Epub 2008 Jan 8.

PMID:
21291713
7.

Update on the detection and treatment of atherogenic low-density lipoproteins.

Sniderman A, Kwiterovich PO.

Curr Opin Endocrinol Diabetes Obes. 2013 Apr;20(2):140-7. doi: 10.1097/MED.0b013e32835ed9cb. Review.

PMID:
23422241
8.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
9.

ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients.

Liem AH, van de Woestijne AP, Roeters van Lennep HW, Zwinderman AH, van der Steeg WA, Jukema JW.

Curr Med Res Opin. 2008 Feb;24(2):359-64.

PMID:
18081989
10.

New dimension of statin action on ApoB atherogenicity.

Chapman MJ, Caslake M, Packard C, McTaggart F.

Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10. Review.

11.

Intensive statin therapy for Indians: Part-I. Benefits.

Enas EA, Pazhoor HC, Kuruvila A, Vijayaraghavan K.

Indian Heart J. 2011 May-Jun;63(3):211-27. Review.

PMID:
22734339
13.

Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.

Kappelle PJ, Zwang L, Huisman MV, Banga JD, Sluiter WJ, Dallinga-Thie GM, Dullaart RP.

Expert Opin Ther Targets. 2009 Jul;13(7):743-51. doi: 10.1517/14728220903023866.

PMID:
19505224
14.

Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?

Rana JS, Boekholdt SM.

Curr Opin Cardiol. 2010 Nov;25(6):622-6. doi: 10.1097/HCO.0b013e32833f0365. Review.

PMID:
20852414
15.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program.

J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. Review.

PMID:
15358046
16.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program.

Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. Review.

17.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association.

Circulation. 2004 Jul 13;110(2):227-39. Review. Erratum in: Circulation. 2004 Aug 10;110(6):763.

18.

Managing dyslipidemia in the high-risk patient.

Stein EA.

Am J Cardiol. 2002 Mar 7;89(5A):50C-57C. Review.

PMID:
11900720
19.

Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?

Sniderman A, McQueen M, Contois J, Williams K, Furberg CD.

J Clin Lipidol. 2010 May-Jun;4(3):152-5. doi: 10.1016/j.jacl.2010.03.005. Epub 2010 Mar 18. Review.

PMID:
21122647
20.

A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.

Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD.

Circ Cardiovasc Qual Outcomes. 2011 May;4(3):337-45. doi: 10.1161/CIRCOUTCOMES.110.959247. Epub 2011 Apr 12.

Supplemental Content

Support Center